These agents increased the expression of pro-metastatic proteins, including HIF1α and vascular endothelial growth factor (VEGF), and stabilized NRF2, which resulted in increased expression of endogenous antioxidants and reduced ROS levels in cancer cells (Wang et al, 2016). The gene discussed is NFE2L2; the disease is cancer.